COVID-19 and Sarcoidosis: A two-way possible association

Hamidreza Bashiri, Mohammadreza Mirjalili, Fahimeh Rashidi Maybodi


Immunological impairments such as lymphopenia in patients with sarcoidosis and their treatment by glucocorticoids and cytotoxic drugs may increase the risk of severe bacterial and viral infections, so these people may be more susceptible to COVID-19 as a disease with viral source. On the other hand, many previous studies pointed to viral trigger in sarcoidosis but no specific virus was mentioned. A recent French cross sectional study on 482 patients, suggests that daily active tobacco smokers have a lower risk of developing severe or symptomatic COVID-19 as compared to nonsmokers. It should be mentioned that our primary observations during the first COVID-19 outbreak (February-April 2020) on 206 COVID-19 patients admitted in intensive care units in Shahid Sadoughi hospital, Yazd, Iran, showed a possible negative association between smoking and coronavirus-2 infection. An observation that was addressed in the literature for sarcoidosis. Some previous studies mentioned that current smokers also have less probability for developing sarcoidosis. According to all these comparable features in patients with COVID-19 and sarcoidosis, may be one day in future, it will be reported that a sarcoidosis-like disease found in patients with COVID-9 history in 2020. Who knows?



Coronovirus, COVID-19, sarcoidosis, association

Full Text:



Clerkin JK, Fried JA, Raikhelkar J, Sayer J, Griffin JM. COVID-19 and cardiovascular disease. Circulation 141:1648-1655, 2020.

Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 94:44-48, 2020.

Jordan RE, Adab P, Cheng KK. Covid-19: Risk factors for severe disease and death. Brit Med J 368: m1198, 2020.

Favalli EG, Ingegnolia F, De Luciaa O, Cincinelli G. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020; 2020.03.001.

Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharmaceut Anal 10:102-108, 2020.

Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 27: taaa041, 2020.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21, 2020.

Fang L, Karakiulakis G, Roth M. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med 8:e32-e33, 2020.

Bergantini L, Bianchi F, Cameli P, Mazzei MA. Prognostic biomarkers of sarcoidosis: A comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers 2019; ID 8565423.

Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin converting enzyme in sarcoidosis: A population-based study. Lung 194:91-95, 2016.

Sarı G, Kurt E, Saydam F. Association between I/D polymorphism in the ACE gene and sarcoidosis in Turkish patients. Cytotechnology 67:1067-1072, 2015.

Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 53:368-370, 2020.

Georas SN, Chapman TJ. Sarcoidosis and T-helper cells Th1, Th17, or Th17.1? Am J Respir Crit Care Med 193:1198-1200, 2016.

Levin AM, Adrianto I, Datta I, Iannuzzi MC. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. Am J Respir Cell Mol Biol 53: 206-216, 2015.

Doğan C, Cömert SS, Çağlayan B. Is Lymphopenia Detected in Sarcoidosis Associated with the Disease Activity? South. Clin. Ist. Euras 30:151-157, 2019.

Tan L, Wang Q, Zhang D. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct Targeted Ther 5:33. doi: 10.1038/s41392-020-0148-4.

Nunes H, Uzunhan Y, Gille T. Imaging of sarcoidosis of the airways a nd lung parenchyma and correlation with lung function. Eur Respir J 40: 750-765, 2012.

Duréault A, Chapelon C, Biard L. Severe infections in sarcoidosis Incidence, predictors and long-term outcome in a cohort of 585 patients. Medicine 96:49(e8846), 2017.

Rossides M, Kullberg S, Askling J. Are infectious diseases risk factors for sarcoidosis or a result of reverse causation? Findings from a population‑based nested case-control study. European J Epidemiol 2020;


Miyara M, Tubach F, Pourcher V. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Open access 2020. DOI: 10.32388/WPP19W.

Ungprasert P, Crowson CS, Matteson EL. Smoking, obesity and risk of sarcoidosis: A population-based nested case-control study. Respir Med 120: 87-90, 2016.

Urbankowski T, Knyziak-Medrzycka I, Domagała-Kulawik J, Chazan R. Sarcoidosis and tobacco smoking-clinical picture, diagnostic tests results and bronchoalveolar lavage fluid composition. Pol Merkur Lekarski 32:298-301, 2012.


  • There are currently no refbacks.